Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.
Yamanaka
Ryuya
R
Homma
Junpei
J
Sano
Masakazu
M
Tsuchiya
Naoto
N
Yajima
Naoki
N
Takahashi
Hideaki
H
Shinbo
Yoshikatsu
Y
Hasegawa
Akira
A
Saitoh
Takashi
T
Tanaka
Ryuichi
R
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003561:Cytarabine / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use; D000069283:Rituximab; D016879:Salvage Therapy / Q000379:methods*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D003561:Cytarabine; D000069283:Rituximab; D003907:Dexamethasone; D008942:Mitoxantrone